Life Sciences News in Poland – July 2026

Has the long-standing ban on pharmacy advertising finally paved the way for a significant shift in how pharmacies communicate with patients? The draft amendment to the Pharmaceutical Law, prepared following the CJEU ruling, sets out a new framework for advertising activities carried out by pharmacies and pharmacy outlets. Deregulation, digitalization, and greater transparency in the healthcare system are trends that are increasingly shaping the legal environment of the Life Sciences sector. July 2026 brought further important changes and legislative initiatives in the areas of pharmaceuticals, healthcare, medical professions, food, and medical devices.

In the latest DLA Piper Poland newsletter, Andrzej Balicki, Ph.D., Jolanta Dąbrowicz, and Patrycja Rzepecka discuss, among other topics:

• new rules on pharmacy advertising following the CJEU ruling,
• digitalization of advertising obligations for medicinal products,
• deregulatory changes to the Pharmaceutical Law,
• the latest EMA guidelines and publications,
• greater transparency of competitions for healthcare services,
• changes to the National Oncology Network and the digitalization of the DiLO card,
• new employment and remuneration obligations for medical personnel,
• the proposed reform of the rules governing the employment of healthcare workers,
• planned changes to the sugar tax,
• the development of the EPS and P1 systems.

We invite you to read the full summary.

If you have any questions regarding the impact of these new regulations on your business, please do not hesitate to contact us.